Search Results for "rapid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for rapid. Results 1 to 10 of 112 total matches.
Comparison Chart: Correct Use of Inhalers for Asthma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
inhaler
▶ Drug delivery to the lungs is dependent upon ability to perform a rapid, deep
inhalation ...
View the Comparison Chart: Correct Use of Inhalers for Asthma
Med Lett Drugs Ther. 2024 Nov 25;66(1716):e196-8 doi:10.58347/tml.2024.1716c | Show Introduction Hide Introduction
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent ...
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent surgical/invasive procedure. It is the second
four-factor PCC to become available in the US;
Kcentra, which has been available since 2013, is
approved for the same indication and for urgent
reversal of warfarin anticoagulation in adults with
acute major bleeding. Balfaxar is marketed in Canada
and Europe as Octaplex.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):31-2 doi:10.58347/tml.2024.1696d | Show Introduction Hide Introduction
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 07, 2020 (Issue 1606)
powder inhaler
Drug delivery to the lungs is dependent upon ability to perform a rapid,
deep inhalation ...
View the Table: Correct Use of Inhalers for COPD
In Brief: New Labeling for Once-Monthly Subcutaneous Buprenorphine (Sublocade)
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025 (Issue 1726)
buprenorphine (rapid
induction) or 7-14 days of transmucosal treatment
(standard induction). The rate ...
The FDA has approved changes to the labeling of
Sublocade (Indivior), an extended-release formulation
of the partial opioid agonist buprenorphine, to permit
faster initiation and use of alternative injection
sites. Sublocade is indicated for once-monthly
subcutaneous treatment of moderate to severe opioid
use disorder.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):63-4 doi:10.58347/tml.2025.1726e | Show Introduction Hide Introduction
Lyumjev - A New Insulin Lispro for Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
in 2017.1
THE NEW PRODUCT — Lyumjev contains insulin lispro
(Humalog, and generics; Admelog2), a rapid ...
The FDA has approved insulin lispro-aabc (Lyumjev –
Lilly), a faster-acting formulation of insulin lispro
(Humalog), for treatment of type 1 and type 2 diabetes
in adults. Fiasp, a faster-acting formulation of insulin
aspart (Novolog), was approved in 2017.
Terlipressin (Terlivaz) for Hepatorenal Syndrome
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
in adults
with hepatorenal syndrome (HRS) and a rapid decline
in kidney function. Terlipressin ...
The FDA has approved the intravenously administered
synthetic vasopressin analog terlipressin (Terlivaz –
Mallinckrodt) to improve kidney function in adults
with hepatorenal syndrome (HRS) and a rapid decline
in kidney function. Terlipressin is the first drug to be
approved for this indication in the US; it has been
available in Europe and elsewhere for year
Med Lett Drugs Ther. 2023 Mar 20;65(1672):46-8 doi:10.58347/tml.2023.1672c | Show Introduction Hide Introduction
In Brief: A Home Test for Chlamydia, Gonorrhea, and Trichomoniasis
The Medical Letter on Drugs and Therapeutics • May 12, 2025 (Issue 1728)
for
chlamydia and gonorrhea. JAMA 2024; 331:1701.
2. SR Morris et al. Performance of a single-use, rapid, point ...
The FDA has authorized use of the Visby Medical
Women's Sexual Health Test (Visby), an at-home
test available without a prescription, for detection of
Chlamydia trachomatis, Neisseria gonorrhoeae, and
Trichomonas vaginalis infections in women with and
without symptoms. It is the first test to become available
in the US for these sexually transmitted infections
(STIs) that can be performed entirely at home. Other
at-home tests are available in the US for diagnosis of
chlamydia, gonorrhea, and trichomoniaisis, but they
require mailing a urine or blood sample to a...
Med Lett Drugs Ther. 2025 May 12;67(1728):80 doi:10.58347/tml.2025.1728e | Show Introduction Hide Introduction
Tramadol Oral Solution (Qdolo) for Pain
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
may not experience an analgesic
effect and CYP2D6 ultra-rapid metabolizers may
have more adverse effects.
Table 1 ...
The opioid agonist tramadol is now available in an oral
solution (Qdolo – Athena Bioscience) for management
of pain severe enough to require an opioid and for
which alternative treatment options are inadequate.
Tramadol has been available for years in immediate-release
tablets and capsules, extended-release
capsules (Ultram, and others), and in a fixed-dose
combination tablet with acetaminophen (Ultracet,
and generics).
Comparison Table: Inhaled Drugs for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
coordination
▶ DPIs require ability to perform a rapid, deep inhalation
36.00
57.00
68.20
26.407 ...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7 doi:10.58347/tml.2024.1710b | Show Introduction Hide Introduction
Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
; also
called Berger's disease) who are at risk of rapid
disease progression. It is the first drug ...
The FDA has approved Tarpeyo (Calliditas), a delayed-release
capsule formulation of the corticosteroid
budesonide, to reduce proteinuria in adults with
primary immunoglobulin A nephropathy (IgAN; also
called Berger's disease) who are at risk of rapid
disease progression. It is the fi rst drug to be approved
in the US for this indication. Oral formulations
of budesonide have been available for years for
treatment of inflammatory bowel disease.